Table 6. Factors associated with nonadherence, multivariable analysis, post 60-day data, 2001–2002^a.

Variable	Participants reporting non-adherence (1–59 days of antimicrobial prophylaxis) among persons taking at least one dose
	Florida (n=744) OR (95% CI)	New Jersey (n=1,028) OR (95% CI)	Hart Senate Building (n=472) OR (95% CI)	Brentwood facility (n=1,619) OR (95% CI)	New York City (n=882) OR (95% CI)	Connecticut (n=598) OR (95% CI)
Gender
Male	1.00 (0.71, 1.41)	0.56 (0.42, 0.76)	0.92 (0.61, 1.38)	0.90 (0.71, 1.13)	0.57 (0.41, 0.79)	0.99 (0.67, 1.46)
Female	Referent	Referent	Referent	Referent	Referent	Referent
Age
17–39 yr	Referent	Referent	Referent	Referent	Referent	Referent
40–64 yr	0.51 (0.36, 0.72)	0.54 (0.40, 0.73)	0.82 (0.53, 1.28)	0.42 (0.32, 0.56)	0.61 (0.41, 0.90)	0.96 (0.64, 1.44)
>65 yr	0.73 (0.28, 1.89)	0.51 (0.23, 1.12)	n/a	0.49 (0.24, 1.02)	0.17 (0.08, 0.39)	0.21 (0.07, 0.65)
Race
African-American	1.80 (0.66, 4.92)	1.47 (1.06, 2.05)	1.87 (1.08, 3.25)	0.90 (0.63, 1.28)	1.08 (0.76, 1.52)	1.39 (0.86, 2.24)
All others	Referent	Referent	Referent	Referent	Referent	Referent
Ethnicity
Hispanic	0.78 (0.47, 1.29)	2.42 (1.21, 4.86)	1.58 (0.42, 6.01)	0.62 (0.23, 1.69)	1.57 (1.03, 2.39)	1.42 (0.68, 2.93)
Non-Hispanic	Referent	Referent	Referent	Referent	Referent	Referent
Adverse events
Yes	2.23 (1.61, 3.09)	1.08 (0.82, 1.44)	1.07 (0.71, 1.62)	0.98 (0.77, 1.24)	1.58 (1.16, 2.16)	1.32 (0.92, 1.90)
No	Referent	Referent	Referent	Referent	Referent	Referent
IND enrollment
Yes	0.36 (0.21, 0.64)	0.27 (0.19, 0.38)	0.09 (0.04, 0.24)	0.28 (0.22, 0.36)	0.33 (0.21, 0.52)	0.64 (0.39, 1.05)
No	Referent	Referent	Referent	Referent	Referent	Referent

^aOR, odds ratio; CI, confidence interval; IND, investigational new drug.